Farther Finance Advisors LLC Has $40,000 Stock Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Farther Finance Advisors LLC trimmed its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 38.1% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,664 shares of the biopharmaceutical company’s stock after selling 1,026 shares during the quarter. Farther Finance Advisors LLC’s holdings in Catalyst Pharmaceuticals were worth $40,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of CPRX. Sanctuary Advisors LLC lifted its stake in shares of Catalyst Pharmaceuticals by 91.5% in the fourth quarter. Sanctuary Advisors LLC now owns 59,447 shares of the biopharmaceutical company’s stock valued at $1,241,000 after buying an additional 28,407 shares in the last quarter. Natixis Advisors LLC lifted its stake in shares of Catalyst Pharmaceuticals by 29.8% in the fourth quarter. Natixis Advisors LLC now owns 59,253 shares of the biopharmaceutical company’s stock valued at $1,237,000 after buying an additional 13,616 shares in the last quarter. Teacher Retirement System of Texas lifted its stake in shares of Catalyst Pharmaceuticals by 18.7% in the fourth quarter. Teacher Retirement System of Texas now owns 31,655 shares of the biopharmaceutical company’s stock valued at $661,000 after buying an additional 4,996 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its stake in shares of Catalyst Pharmaceuticals by 7.0% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 21,419 shares of the biopharmaceutical company’s stock valued at $447,000 after buying an additional 1,402 shares in the last quarter. Finally, Victory Capital Management Inc. lifted its position in shares of Catalyst Pharmaceuticals by 1.6% during the fourth quarter. Victory Capital Management Inc. now owns 296,080 shares of the biopharmaceutical company’s stock valued at $6,179,000 after purchasing an additional 4,575 shares in the last quarter. 79.22% of the stock is currently owned by institutional investors and hedge funds.

Catalyst Pharmaceuticals Price Performance

NASDAQ:CPRX opened at $22.07 on Wednesday. The firm’s 50-day moving average price is $23.91 and its 200-day moving average price is $22.90. The company has a market capitalization of $2.69 billion, a PE ratio of 14.06, a P/E/G ratio of 0.90 and a beta of 0.72. Catalyst Pharmaceuticals, Inc. has a 1-year low of $14.75 and a 1-year high of $26.58.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the stock. HC Wainwright restated a “buy” rating and set a $35.00 price objective on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th. Robert W. Baird raised their price objective on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an “outperform” rating in a report on Monday, March 3rd. Wall Street Zen upgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, February 28th. Cantor Fitzgerald upgraded shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Thursday, June 5th. Finally, Stephens restated an “overweight” rating and set a $33.00 price objective on shares of Catalyst Pharmaceuticals in a report on Thursday, February 27th. Six equities research analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, Catalyst Pharmaceuticals presently has an average rating of “Buy” and an average price target of $32.83.

Insider Buying and Selling

In other Catalyst Pharmaceuticals news, insider Gary Ingenito sold 44,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 14th. The shares were sold at an average price of $23.63, for a total value of $1,039,720.00. Following the completion of the transaction, the insider now directly owns 68,873 shares in the company, valued at $1,627,468.99. This represents a 38.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Preethi Sundaram sold 1,600 shares of the company’s stock in a transaction on Wednesday, June 11th. The shares were sold at an average price of $26.42, for a total transaction of $42,272.00. Following the sale, the insider now directly owns 41,081 shares in the company, valued at approximately $1,085,360.02. The trade was a 3.75% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 247,924 shares of company stock valued at $5,879,369. 10.40% of the stock is owned by insiders.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.